Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JPA to Bolster Strategies for Key Issues thru Policy Study Committee: Pres. Kodama
July 2, 2013
- JMA Sets Up Pharmaceutical Affairs Section
July 1, 2013
- Generic Share Reaches 25.8% by Volume, 10.5% by Price in FY2012: JGA
July 1, 2013
- JGA to Establish New Membership Category to Encourage Non-Member Companies to Provide Information through Its Website
June 27, 2013
- JGA Concerned about TPP Talks, Hopes Japan Will Adopt US Rules Favorable to Generic Makers
June 24, 2013
- JPMA Weighs Scheme to Allow Use of Clinical Research Evidence for Drug Applications
June 21, 2013
- Generic-Only Distributors Total 485, Only 17% Are Member Companies: Generic Distributor Association Survey
June 13, 2013
- FPMAJ Subcommittee Floats New Pricing Rule to Replace Cost Calculation Method
June 12, 2013
- FPMAJ Subcommittee Says NHI Prices of Essential Drugs Should Be Maintained; Stable Supply System for Disasters Envisioned as Requirement
June 11, 2013
- 30% of Newly Listed Drugs in FY2012 Developed at Request of Govt: FPMAJ Survey
June 10, 2013
- FPMAJ Committee Appoints Eisai’s Tsuchiya, Takeda’s Aoyagi as Vice Chairman
June 7, 2013
- Consumers Need to Take Caution with Online OTC Drug Sales: Keizai Doyukai Chairman Hasegawa
June 7, 2013
- Lifting of Ban on Online OTC Drug Sales Would “Create Situation of Grave Concern”: JMA Vice President Nakagawa
June 7, 2013
- Pros and Cons of Bungyo Should Be Reconsidered: JMARI Working Paper
June 6, 2013
- Sawai Gains Steady Market Shares of Generics in Broad Categories, Meiji Seika Pharma Strong in CNS: Survey
June 4, 2013
- ACCJ, EBC Advocate Preventive Health, Say Physicians Should Earn More by Keeping People Out of Hospitals
June 3, 2013
- Fewer Drug Makers Used Outside Organizations for MR Education and Training in FY2012: MREAC
June 3, 2013
- Drug Makers, R&D Organizations Sign Memorandum to Search Compounds for Infectious Disease Treatment: GHIT Fund
June 3, 2013
- JMA Demands Novartis Disclose Details of Internal Probe
May 31, 2013
- Actions Taken in 29 Prefectures to Eliminate Free Benefits and Labor Provided by Wholesalers: Industry FTC Reports
May 29, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…